Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits their availability for those who need them. Part of the reason for the cost is that the manufacturing process yields as much as 90% non-active material, and separating out these useless parts is slow, leads to significant losses, and is not well adapted to large-scale production.
